

ACKNOWLEDGEMENTS

To Drs. K.W. Hindmarsh and S.M. Wallace whose advice and encouragement has made completion of this thesis possible.

To Drs. A.J. Remillard, J.W. Hubbard, G.M. Wyant, D. Danilkewich and Dean J. Blackburn for their interest and invaluable assistance in this research.

To the many individuals who provided guidance and support during the course of this research work.

To the Medical Research Council of Canada for their generous financial support.

THE EFFECTS OF CHRONIC ACETAMINOPHEN ADMINISTRATION
ON THE DISPOSITION OF THE DRUG
AND THE BODY STORES OF SULPHATE

A Thesis

submitted to the Faculty of Graduate Studies & Research
in Partial Fulfillment of the Requirements
for the Degree of
Master of Science in Pharmacy

by

Shirley Hendrix-Treacy B.S.P.

Saskatoon, Saskatchewan

(c) 1985 S.A. Hendrix-Treacy

The author has agreed that the Library, University of Saskatchewan, may make this thesis freely available for inspection. Moreover, the author has agreed that permission for extensive copying of this thesis for scholarly purposes may be granted by the professor or professors who supervised the thesis work recorded herein or, in their absence, by the Head of the Department or the Dean of the College in which the thesis work was done. It is understood that due recognition will be given to the author of this thesis and to the University of Saskatchewan in any use of the material in this thesis. Copying or publication or any other use of the thesis for financial gain without approval by the University of Saskatchewan and the author's written permission is prohibited.

Requests for permission to copy or to make any other use of material in this thesis in whole or in part should be addressed to:

Dean of the College of Pharmacy
University of Saskatchewan
Saskatoon, Canada S7N 0W0

ABSTRACT

Acetaminophen is a common non-prescription drug used as an analgesic for mild to moderate pain, and as an antipyretic. In therapeutic doses, it is well tolerated but ingestion of excessive amounts of acetaminophen (greater than 5 g) is associated with hepatotoxicity.

The present study examined the effects of long term ingestion of therapeutic dosages of acetaminophen. Little information is known about the effects of acetaminophen on important cosubstrates (sulfate and glutathione, in particular) during chronic administration. Of particular importance are the recent findings that even a single dose of 1.5 g of acetaminophen can cause partial depletion of body stores of sulfate in man (Morris & Levy, 1983).

To study the effects of acetaminophen on sulfate levels in the body, a turbidimetric assay for the determination of inorganic sulfate in biological fluids was used. Acetaminophen and key metabolites in urine were analyzed by a rapid, sensitive and specific high pressure liquid chromatographic procedure. Calibration curves were linear over the concentration range of acetaminophen and metabolites expected. Extraction efficiency for acetaminophen from serum was 82.5 (± 2.3 SD)%.

The study included nine (9) healthy volunteers and ten (10) patients receiving acetaminophen on a chronic basis. Volunteers participated on two occasions; on the first, each received a single 650 mg oral dose of acetaminophen, and the second time, each received a total of 3.25 g of acetaminophen over a 30 hour time period (650 mg every 6 hours).

Patients participating in the study were maintained on their normal treatment and dosage schedules. Concentration of acetaminophen in serum (over 8 h for the volunteer studies; single sample for patients) and acetaminophen and its metabolites in urine (24 hour collection for volunteers; single void for patients) were determined.

The maximum serum concentration of acetaminophen ranged from 3.79 - 8.63 $\mu\text{g/mL}$ for the single dose and 6.81 - 29.63 $\mu\text{g/mL}$ for multiple dosing in volunteers. Mean values for C_{max} were significantly higher in the multiple dose study ($13.29 \pm 6.35 \mu\text{g/mL}$) compared to the single dose ($7.12 \pm 1.36 \mu\text{g/mL}$) ($p < 0.05$). However accumulation was not greater than predicted based on the half-life and dosing interval, indicating that the overall disposition of acetaminophen did not differ significantly after multiple dosing.

The total recovery of the single dose (650 mg) of acetaminophen administered in this study averaged 86.8 (± 7.2 SD)%. Of the total acetaminophen and metabolites recovered in the urine, 47.7 (± 9.3)% consisted of the glucuronide conjugate, 46.9 (± 9.4)% the sulfate conjugate, and 5.4 (± 5.7)% unchanged drug. The pattern of acetaminophen elimination was significantly different after multiple dosing and after chronic administration ($p < 0.05$). The sulfate conjugate fraction excreted in urine decreased, the glucuronide increased but the fraction excreted as the parent compound remained the same. This decrease in the sulfate conjugate is consistent with saturation of sulfate pathway, whereupon glucuronidation becomes the preferred route of metabolism (evidenced by the increase in glucuronide fraction).

Inorganic sulfate levels in serum over an 8 hour period were affected by the administration of single as well as multiple doses of acetaminophen. Serum levels of inorganic sulfate in volunteers fluctuated (transient increase seen in single dosing), and dropped to a minimum level approximately 2 hours after acetaminophen administration. In addition, multiple dosing produced a decrease in the mean inorganic sulfate level ($p < 0.05$) and a decrease in the renal clearance of inorganic sulfate, during at least, the first 4 hours after dosing ($p < 0.05$). Assuming that serum sulfate levels reflect the body stores of sulfate, a drop in serum sulfate is expected to be the result of depletion in the sulfate stores in the body, because the body probably would not be able to compensate sufficiently for the increased and continuous need for sulfate in the metabolism of acetaminophen. The decrease seen in the renal clearance of sulfate is thought to be a compensatory mechanism available to help maintain sulfate stores in the body when there is an increased need for sulfate. Unexpectedly, patients on chronic acetaminophen administration showed elevated serum sulfate levels. This is also likely the result of a feedback mechanism (i.e. decreased renal clearance and/or increased sulfate formation).

It is possible that the body is able to compensate sufficiently when there is a prolonged increased need for sulfate and that those taking therapeutic doses of acetaminophen chronically are not at increased risk of liver damage. However further study is needed.

TABLE OF CONTENTS

	PAGE
ACKNOWLEDGEMENTS	iii
ABSTRACT	iv
LIST OF TABLES	x
LIST OF FIGURES	xi
LITERATURE REVIEW	1
1. Acetaminophen	1
1.1 History	1
1.2 Therapeutic Use	3
1.3 Pharmacokinetics	5
1.3.1 Absorption	5
1.3.2 Distribution	5
1.3.3 Elimination	7
1.3.3.1 Following Therapeutic Dosage	7
1.3.3.2 Following Acute Overdosage	9
1.4 Toxicity	10
1.4.1 Symptoms of Toxicity	10
1.4.2 Prediction of Liver Damage	12
1.4.3 Treatment of Acute Toxicity	12
1.4.4 Factors Influencing Toxicity	15,
2. Sulfate as a Cosubstrate	17
2.1 Introduction	17
2.2 Kinetics	18
2.3 Availability of Inorganic Sulfate as a Rate-Limiting Factor in Drug Metabolism	20

3.	Analytical Methods	21
3.1	Acetaminophen and Its Metabolites	21
3.2	Inorganic Sulfate	22
4.	The Present Investigation	25

EXPERIMENTAL	27
--------------	----

1.	Analytical Techniques	27
1.1	Spectrophotometric Assay of Inorganic Sulfate	27
1.1.1	Analysis of Serum	27
1.1.2	Analysis of Urine	27
1.1.3	Construction of Calibration Curves	28
1.2	High Pressure Liquid Chromatographic Assay of Acetaminophen and Its Metabolites	29
1.2.1	Extraction from Biological Fluids	29
1.2.2	Chromatographic Conditions	31
1.2.3	Construction of Calibration Curves	32
2.	The Clinical Study	33
2.1	Subject Selection	33
2.2	Collection and Storage of Biological Samples	34
2.3	Analysis of Samples	35
2.4	Data Analysis	36

RESULTS	38
1. Analytical Methodology	38
1.1 Spectrophotometric Assay for Inorganic Sulfate	38
1.2 High Pressure Liquid Chromatographic Assay of Acetaminophen and Its Metabolites	42
1.2.1 Extraction from Biological Fluids	42
1.2.2 Analysis	44
1.2.3 Calibration Curves	47
1.2.4 Evaluation of the Assay	48
2. The Clinical Study	52
2.1 The Study Group	52
2.2 Disposition of Acetaminophen	55
2.2.1 In Volunteers	55
2.2.2 In Patients	58
2.3 Effect of Multiple Dosing on Urinary Excretion of Acetaminophen	60
2.3.1 In Volunteers	60
2.3.2 In Patients	60
2.4 Effect of Acetaminophen Administration on Inorganic Sulfate Kinetics	62
2.4.1 In Volunteers	62
2.4.2 In Patients	67
DISCUSSION	70
SUMMARY AND CONCLUSIONS	86
RECOMMENDATIONS FOR FUTURE RESEARCH	88

APPENDICES		90
Appendix I:	Materials, Solvents, Reagents	90
Appendix II:	Apparatus	91
Appendix III:	Forms Used for Documentation of Data	93
Appendix IV:	Data Used to Construct Calibration Curves (UV Spectrophotometry)	97
Appendix V:	Data Used to Construct Calibration Curves & Determine Extraction Efficiency of High Pressure Liquid Chromatography	98
Appendix VI:	Formulas Used to Calculate Tables Values	103
Appendix VII:	Clinical & Analytical Data for the Study Groups	104
REFERENCES		112

LIST OF TABLES

	PAGE
I. High pressure liquid chromatographic analysis of acetaminophen in blood	23
II. High pressure liquid chromatographic analysis of acetaminophen and its metabolites in plasma and urine	24
III. Calibration curves for ultra-violet-visible spectrophotometric analysis for inorganic sulfate in serum and urine	41
IV. Calibration curves for high pressure liquid chromatographic analysis of acetaminophen and its metabolites in biological fluids	50
V. Acetaminophen serum levels in patients	54
VI. Disposition of acetaminophen in volunteers - single and multiple dose studies	56
VII. Excretion of acetaminophen and its metabolites in urine - volunteers	61
VIII. Excretion of acetaminophen and its metabolites in urine - patients	63
IX. Comparison of acetaminophen metabolite excretion in volunteers (multiple dosing) and patients (chronic dosing)	64
X. Serum levels of inorganic sulfate in volunteers	66
XI. Renal clearance of inorganic sulfate in volunteers	68
XII. Effect of acetaminophen on inorganic sulfate levels (in patients)	69
XIII. Acetaminophen sulfate (%) recovered in urine per time interval - volunteers	75
XIV. Effect of acetaminophen on serum sulfate concentrations with time - volunteer studies	79

LIST OF FIGURES

		PAGE
Figure 1	Phenacetin metabolism in man	2
Figure 2	Antipyretic action of acetaminophen	4
Figure 3	Modified two-compartment pharmacokinetic model of acetaminophen in man	6
Figure 4	Metabolism of acetaminophen in man	8
Figure 5	Relationship between plasma concentration, time after ingestion, and liver damage after acetaminophen overdose	13
Figure 6	Conversion of methionine and cysteine to inorganic sulfate in man and activation of this cosubstrate in metabolism	19
Figure 7	Calibration curves for inorganic sulfate in serum (A) and urine (B) (UV-VIS spectrophotometry)	40
Figure 8	High pressure liquid chromatograms of A) blank serum extract; B) extract of serum containing: I, acetaminophen (10 ug/mL); II, internal standard (10 ug/mL) (mobile phase: 20% methanol: 0.2% glacial acetic acid; 5% acetonitrile in water).	46
Figure 9	High pressure liquid chromatograms of A) blank urine (diluted); B) diluted urine (3 x) containing: I, acetaminophen sulfate (28.9 ug); II, acetaminophen glucuronide (46.2 ug); III, acetaminophen (3.6 ug); IV, internal standard (50.0 ug/mL) (mobile phase: 15% methanol: 0.2% glacial acetic acid in water).	48
Figure 10	Calibration curve for acetaminophen in serum (high pressure liquid chromatography)	49
Figure 11	Calibration curves for acetaminophen in urine (A) and acetaminophen sulfate (●) and glucuronide (o) in urine (B) (high pressure liquid chromatography)	51

Figure 12	Acetaminophen concentration-time profile of volunteers (mean values)	57
Figure 13	Acetaminophen concentration-time profile of one volunteer (J.M.)	59
Figure 14	Concentration-time curves of inorganic sulfate in the body (single dose (●) and multiple dose (o) studies) for volunteers S.H. (A) and C.H. (B).	65

LITERATURE REVIEW

1. Acetaminophen

1.1 History

Acetaminophen (paracetamol; N-acetyl-p-aminophenol) was first synthesized at John Hopkin's University in 1877. However, it was not until 1893 that it was introduced by Von Mehring into medical therapy (Spooner & Harvey, 1976). At that time very little attention was paid to the new drug. Side effects were frequent and two similar drugs, phenacetin and acetanilid, were already available. Use of acetaminophen did not become extensive until 1949, when Brodie and associates (1949) recognized it to be the principle active metabolite of acetanilid and phenacetin. They proved that acetaminophen was responsible for the analgesic and antipyretic activity of these two more toxic drugs yet, unlike phenacetin, it did not cause methemoglobinemia (Figure 1).

In 1950, acetaminophen was marketed in the United States in an analgesic mixture as a substitute for phenacetin. One year later, however, the manufacturer recalled the drug after several reported incidences of blood dyscrasias. Acetaminophen was available again in 1952, but this time only on prescription. Since 1955, acetaminophen has been marketed without a prescription in the United States and Canada and evidence indicates that its use has been steadily increasing (Manoquerra, 1979).




Figure 1: Phenacetin Metabolism in Man (Peterson & Rumack, 1978)

1.2 Therapeutic Use

Acetaminophen is a non-narcotic antipyretic/analgesic that is used not only in adults, but also in children and infants. It has been classified as an "Aspirin^R substitute" since its therapeutic properties are similar to those of A.S.A. (acetylsalicylic acid, Aspirin^R) (Yaffe, 1981). Both drugs are equally effective as antipyretics. They lower body temperature by altering the response of the hypothalamus to pyrogens (by interfering with the synthesis and release of prostaglandins from the anterior hypothalamus). The effect on this heat-regulating center is to cause a lowering of the set point in the hypothalamus thus activating mechanisms of heat loss -- cutaneous vasodilation and sweating (Lovejoy, 1978) (Figure 2).

The analgesic effect appears to be the result of the ability to inhibit the biosynthesis of prostaglandins and the most abundant precursor of prostaglandin, arachidonic acid (Meredith & Goulding, 1980). However, unlike A.S.A., acetaminophen's analgesic effect is not associated with anti-inflammatory activity in the usual therapeutic doses (Hinson et al., 1980). This is due to different sensitivities of central and peripheral prostaglandin synthetase enzymes in the anterior hypothalamus. Acetaminophen is a potent inhibitor of central prostaglandin synthetase while A.S.A. inhibits both central and peripheral enzymes.

Acetaminophen has many advantages over A.S.A. Acetaminophen does not inhibit the clotting process, nor does it cause gastric irritation or erosions, when taken in therapeutic dosage (325 - 650 mg, 4 to 6 times daily) (Meredith & Goulding, 1980). It is remarkably free from side effects, with allergic reactions such as skin rashes (Koch-Weser, 1976) and drug fever occurring only rarely.




Figure 2: Antipyretic Action of Acetaminophen (Lovejoy, 1978)
 (cell types shown are: lymphocytes with nongranular cytoplasm, monocytes, with oval or indented nucleus, and granulocytes with multilobed nucleus)

Acetaminophen is commonly used to treat headaches, migraines, neuralgias, and dysmenorrhea and to reduce fever (Savides and Oehme, 1983). It is considered one of the safest of all minor analgesics in therapeutic dosage and is now more widely used than A.S.A. in many countries (Mitchell et al., 1974).

1.3 Pharmacokinetics of Acetaminophen

1.3.1 Absorption

Oral administration of acetaminophen to fasting subjects results in rapid and complete absorption, with peak plasma levels occurring in 20 to 45 minutes (Rumack & Matthew, 1975). Absorption is complete within 4 hours (Prescott, et al., 1971).

Acetaminophen is not absorbed to any extent from the stomach but is almost totally absorbed from the small intestine (Heading et al., 1973) (Figure 3). Since absorption for most drugs is much faster from the small intestine (K_A) than from the stomach (K_A^*), the rate of gastric emptying (K_g) affects the overall rate of absorption into the systemic circulation. Therefore, the rate of absorption can be influenced by factors which alter gastric emptying, including: ingestion of food, certain drugs (eg: narcotic analgesics) (Clements, et al., 1978) and posture (Nimmo & Prescott, 1978; Hayes, 1981). Delayed gastric emptying results in lower peak plasma levels at later times. The extent of absorption, however, is not affected.

1.3.2 Distribution

Acetaminophen is relatively lipid soluble and appears in most body fluids. The volume of distribution is 0.9 - 1.0 L/kg (Forrest et al., 1982). Plasma protein binding of acetaminophen and its




Figure 3: Modified two-compartment Pharmacokinetic model used to describe the gastric emptying pattern of acetaminophen in man (Clements, et al. 1978).

k_{12}, k_{21} - rate constants for transfer into and out of the second body compartment

k_{el} - elimination rate constant from the central compartment

k_g - 1st order rate constant for gastric emptying

k_A^g - rate constant for absorption from the stomach

k_A - rate constant for transfer of drug from the small intestine to systemic circulation

$D_{st}, D_{in}, D_1, D_2, D_{el}$ - quantities in the stomach, small intestine, compartment 1 and 2 and quantity of eliminated drug, respectively.

glucuronide metabolite is low at therapeutic doses (10 - 15%) (Gazzard et al., 1973; Meredith & Goulding, 1980). Acetaminophen sulfate is appreciably bound to serum proteins (greater than 50%) (Morris & Levy, 1984).

Acetaminophen distributes very poorly into human milk. Berlin and associates (1980) found that the fraction of an acetaminophen dose available to an infant through breast milk is less than 1%. Neither acetaminophen nor its metabolites were detected in the urine of nursing infants. This evidence suggests that maternal ingestion of acetaminophen in usual therapeutic doses does not present a risk to the nursing infant. Although acetaminophen is able to cross the placental barrier and enter the fetal circulation, there are no reported teratogenic effects, adverse or maternal effects associated with the use of acetaminophen in therapeutic dosage.

1.3.3 Elimination

1.3.3.1 After Therapeutic Dosing

Acetaminophen is extensively metabolized in the body (Figure 4). Following oral administration, up to 20% of a dose is converted via first pass metabolism to inactive products (Oie, 1975; Ameer & Greenblatt, 1977; Rawlins et al., 1977). The remaining 80% of the dose reaches the systemic circulation where it is metabolized to inactive products in the liver and then excreted in the urine, mainly as the glucuronide and sulfate conjugates (Levy & Yamada, 1971; Mitchell et al., 1974; Mrochek et al., 1974). Only 2 - 5% of a therapeutic dose is excreted unchanged. The remaining 4 - 7% of an acetaminophen dose is transformed via the P_{450} mixed function oxidase enzyme system to a reactive metabolite (Seller & Freedman, 1981; Clements et al., 1983).




Figure 4: Metabolism of Acetaminophen in Man (Savides & Oehme, 1983)

This highly reactive arylating agent, thought to be N-acetyl-p-benzoquinoneimine, (Miner & Kissinger, 1979; Clements et al., 1983) is quickly detoxified by reaction with glutathione to form cysteine and mercapturic acid conjugates.

Excretion of acetaminophen metabolites is rapid and almost exclusively via the kidney, with 90% of a therapeutic dose appearing in the urine within 24 hours (Mitchell et al., 1974). Relative proportions of metabolites excreted in urine after a therapeutic dose of acetaminophen in man are: acetaminophen glucuronide - 55-75%, acetaminophen sulfate - 20-40%, acetaminophen cysteine and mercapturic acid conjugates - 5-10%, and unchanged drug - 1-4% (Levy & Yamada, 1971).

The plasma elimination half-life ($t_{1/2}$) of acetaminophen varies considerably among individuals; the range is 2-4 hours for adults (Miller et al., 1976). Half-life is shorter in children (1.9-2.2 h), somewhat longer in neonates (3.4-3.6 h) and cirrhotic patients (2.1-3.8 h) (Levy et al., 1975; Benson, 1983). The half-life is not prolonged in patients with impaired renal function (Ameer & Greenblatt, 1977). However, in anephric patients, there is accumulation of glucuronide and sulfate metabolites (Lowenthal et al., 1976).

1.3.3.2 Following Acute Overdosage

After a toxic dose of acetaminophen is ingested, changes in metabolism occur. As the dose ingested approaches four grams, sulfate conjugation becomes saturated. With ingestion of greater than 10 grams, the fraction of the dose conjugated with sulfate drops dramatically, from 30 to 9% (Prescott, 1983) and glucuronidation becomes saturated. With both of these pathways saturated, a greater fraction is metabolized via the P_{450} pathway, thus increasing the

percentage of cysteine and mercapturic acid conjugates produced (Howie et al., 1977; Slattery & Levy, 1979). If glutathione stores are depleted by 70% or more, the reactive, toxic metabolite (N-acetyl-p-benzoquinoneimine) begins binding irreversibly to liver macromolecules and/or cell membranes (Mitchell et al., 1974). Centrilobular hepatic necrosis and cell death result. Other vital organs may also be affected, including the heart and kidneys (Hinson, 1983).

With overdose, there is often an increase in half-life ($t_{1/2}$) which is directly related to the extent of liver damage (up to 7 hours for severe hepatic injury) (Prescott et al., 1971). If liver damage does not occur, $t_{1/2}$ increases only slightly.

1.4 Toxicity

Acetaminophen is a remarkably safe agent when used in therapeutic doses. The major concerns with respect to toxicity are related to acute overdosage -- most often the result of attempted suicide (Volans, 1976). The drug is usually taken on impulse for manipulative purposes and most individuals are completely unaware of the possible consequences. There is wide variation between individuals in susceptibility to the toxic effects of acetaminophen, but in an adult, serious toxicity can result after ingestion of 20-30 - 325 mg tablets (6-10 grams).

1.4.1 Symptoms of Toxicity

The symptoms of acute acetaminophen poisoning have been categorized and divided into three phases (Rumack & Matthew, 1975):

- 1) The first phase occurs within the first 24 hours. This stage is clinically deceptive because there is often no acute distress. Some

